1. Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases
- Author
-
Thomas A. Ciulla, Gregory M. Saltzman, Mark W. Johnson, Maria Fernanda Abalem, Rebhi Abuzaitoun, K. Thiran Jayasundera, and Gabrielle D. Lacy
- Subjects
medicine.medical_specialty ,Activities of daily living ,business.industry ,Cost effectiveness ,Cost-Benefit Analysis ,Specialty ,Genetic Therapy ,Cost-effectiveness analysis ,Article ,Clinical trial ,Ophthalmology ,Indirect costs ,Quality of life (healthcare) ,Retinal Diseases ,parasitic diseases ,Health care ,Quality of Life ,medicine ,Humans ,business ,Intensive care medicine - Abstract
PURPOSE: To discuss the challenges and potential improvement strategies of cost-effectiveness analyses performed for therapeutics targeting inherited retinal diseases. DESIGN: Perspective METHODS: Literature review with discussion of current limitations and improvement recommendations. RESULTS: Cost-effectiveness analysis (CEA) performed for inherited retinal diseases (IRD) therapeutics has multiple limitations. First, the available methods used to measure health-related quality of life and health utilities can be inaccurate when used in IRDs. Second, the financial burden to patients and society by vision impairment associated with IRDs has been inadequately studied and includes a variety of expenditures ranging from direct costs of IRD specialty healthcare to indirect expenses associated with daily living activities. Third, our collective understanding is limited in the areas of IRD natural history and health benefits gained from new IRD treatments (e.g. gene therapies). Additionally, the therapeutic effect from a patient perspective and its duration of action is not fully understood. Due to the scarcity of data, CEA for newly approved therapies has relied on assumptions and creations of predictive models for both costs and health benefits for these new therapeutics in order to calculate the incremental cost-effectiveness ratio (ICER). CONCLUSIONS: CEA studies performed for IRD therapeutics have been limited by the currently established health utilities in ophthalmology and the lack of disease-specific information. The assumptions and extrapolations in these studies create substantial uncertainty in ICER results. An improved framework is required for CEA of IRD therapeutics in order to determine the cost-effectiveness of each therapy brought from clinical trials to clinical practice. TABLE OF CONTENTS STATEMENT: Cost-effectiveness analysis (CEA) studies performed for inherited retinal disease (IRD) therapeutics have been limited by the currently established health utilities in ophthalmology which lack disease specific information. The assumptions and extrapolations made in these studies are susceptible to large amounts of uncertainty in incremental cost-effectiveness ratio calculations. An improved framework for CEA of IRD therapeutics would better inform policy makers and other stakeholders, as these therapies progress from preclinical testing to clinical trials, and finally to clinical practice
- Published
- 2022